Shares of Medtronic (NYSE: MDT), one of the world's largest medical device makers, have declined by more than 30% over the past five years. Higher costs, supply chain bottlenecks, quality control issues, and competitive pressure in surgical robotics all weighed on its stock.
Yet Wall Street remains bullish on Medtronic, with an average price target of $98.44 and a top target of $121. I believe it could rise more than 40% from its current price of $86 and hit that high-end target by the end of this year for a few simple reasons.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Back in March, Medtronic spun off its diabetes unit as MiniMed (NASDAQ: MMED) to streamline its business. It's also restructuring its business to expand its higher-margin cardiovascular and neuroscience portfolios and to integrate more AI features into its surgical planning products.
In fiscal 2026 (which ended in April), Medtronic's revenue grew 8.4% to $36.4 billion (or 5.8% organically) and marked its strongest top-line growth in ten years. From fiscal 2026 to fiscal 2029, **** ysts expect its revenue and EPS to grow at CAGRs of 5% and 13%, respectively.
#NVIDIA #years #surgical
Yet Wall Street remains bullish on Medtronic, with an average price target of $98.44 and a top target of $121. I believe it could rise more than 40% from its current price of $86 and hit that high-end target by the end of this year for a few simple reasons.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Back in March, Medtronic spun off its diabetes unit as MiniMed (NASDAQ: MMED) to streamline its business. It's also restructuring its business to expand its higher-margin cardiovascular and neuroscience portfolios and to integrate more AI features into its surgical planning products.
In fiscal 2026 (which ended in April), Medtronic's revenue grew 8.4% to $36.4 billion (or 5.8% organically) and marked its strongest top-line growth in ten years. From fiscal 2026 to fiscal 2029, **** ysts expect its revenue and EPS to grow at CAGRs of 5% and 13%, respectively.
#NVIDIA #years #surgical
3 months ago
